IMUX vs ABBV vs GILD vs BIIB vs INCY

For growth investors, Incyte Corporation (INCY) is the stronger pick with 21.

2% revenue growth year-over-year, versus 1. 4% for Biogen Inc. (BIIB). Incyte Corporation (INCY) offers the better valuation at 16. 8x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Immunic, Inc. (IMUX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 16.

8x versus AbbVie Inc. at 94. 8x. On forward P/E, Biogen Inc. is actually cheaper at 13. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +121. 1%, compared to -90. 8% for Immunic, Inc. (IMUX). Over 10 years, the gap is even starker: ABBV returned +362. 2% versus IMUX's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus Immunic, Inc. 's 1. 80β — meaning IMUX is approximately 1222% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 109% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Incyte Corporation (INCY) is pulling ahead at 21.

2% versus 1. 4% for Biogen Inc. (BIIB). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, INCY leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus 0. 0% for Immunic, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 39. 7% versus 0. 0% for IMUX. At the gross margin level — before operating expenses — INCY leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Biogen Inc.

(BIIB) trades at 13. 7x forward P/E versus 480. 4x for Gilead Sciences, Inc. — 466. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 26. 8% to $159. 56.

In this comparison, ABBV (2.

9% yield), GILD (2. 5% yield) pay a dividend. IMUX, BIIB, INCY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Immunic, Inc. (IMUX) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +362. 2%, IMUX: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMUX is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock; GILD is a mid-cap quality compounder stock; BIIB is a mid-cap quality compounder stock; INCY is a mid-cap high-growth stock. ABBV, GILD pay a dividend while IMUX, BIIB, INCY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.